Niraparib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 928 publications

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.

Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 13, 2026

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.

Journal: RSC advances

Published: April 10, 2026

Combined effects of electroporation and 100 mGy X-ray on the anticancer activity of newly synthesized niraparib-based Schiff base, Pd(II) and Fe(II) complexes in SKOV-3 cancer cells.

Combined effects of electroporation and 100 mGy X-ray on the anticancer activity of newly synthesized niraparib-based Schiff base, Pd(II) and Fe(II) complexes in SKOV-3 cancer cells.

Journal: Bioorganic chemistry

Published: April 07, 2026

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Cancers

Published: March 08, 2026

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models.

Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models.

Journal: Journal of clinical pharmacology

Published: March 03, 2026

A Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance.

A Novel, Robust, and Isocratic HPLC-UV Method for the Comprehensive Determination of Enantiomeric Impurity (R-Isomer) in Niraparib Drug Substance.

Journal: Chirality

Published: February 27, 2026

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.

Journal: Clinical pharmacokinetics

Published: February 25, 2026

Interpretable QSAR and Complementary Docking for PARP1 Inhibitor Prioritization: Reliability Stratification and Near-Domain Screening.

Interpretable QSAR and Complementary Docking for PARP1 Inhibitor Prioritization: Reliability Stratification and Near-Domain Screening.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 21, 2026

Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review.

Multimodal therapy for ovarian cancer with brain metastases diagnosed synchronously at the initial phase: case report of a long-term survivor with comprehensive literature review.

Journal: Gynecologic oncology reports

Published: February 21, 2026

Correspondence on "Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer" by Kim et al.

Correspondence on "Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer" by Kim et al.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 18, 2026

Showing 1-12 of 928

Last Updated: 06/30/2026